A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma
This is a single-center, open-label study to evaluate the safety and efficacy of C-CAR039 in relapsed and/or refractory B-NHL patients.
B-cell Non-Hodgkin's Lymphoma
BIOLOGICAL: Prizloncabtagene Autoleucel
Incidence and severity of adverse events, Incidence and severity of adverse events after C-CAR039 infusion according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0 criteria, Up to 24 months after C-CAR039 infusion
Maximum concentration of C-CAR039 in the peripheral blood (Cmax), Detect CAR-T copies number by qPCR, Up to 24 Months after C-CAR039 infusion|Time to maximum concentration of C-CAR039 in the peripheral blood (Tmax), Detect CAR-T copies number by qPCR, Up to 24 Months after C-CAR039 infusion|Tlast of C-CAR039 in the peripheral blood after infusio (Tlast), Detect CAR-T copies number by qPCR, Up to 24 Months after C-CAR039 infusion|AUC0h-28d of C-CAR039 in the peripheral blood (AUC0-28d), Detect CAR-T copies number by qPCR, Up to 28 days after C-CAR039 infusion|Overall response rate (ORR), Complete response (CR) rate plus partial response (PR) rate by Lugano 2014 criteria, Up to 24 Months after C-CAR039 infusion|Duration of response (DOR), The time from the date of first response (PR or better) to the date of disease progression or death after C-CAR039 infusion, Up to 24 Months after C-CAR039 infusion|Progression-free survival (PFS), The time from C-CAR039 infusion to the date of progression as assessed by Lugano 2014 criteria or death, Up to 24 Months after C-CAR039 infusion|Overall survival (OS), The time from C-CAR039 infusion to the date of death, Up to 24 Months after C-CAR039 infusion
The study will include the following sequential phases: Screening, Apheresis and C-CAR039 manufacturing, Baseline testing, Lymphodepleting, C-CAR039 infusion, and Follow-up Visit.